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ABSTRACT
Soluble epoxide hydrolase (sEH) catalyzes the conversion of
epoxyeicosatrienoic acids into less active eicosanoids, and inhib-
itors of sEH have anti-inflammatory and antiapoptotic properties.
Based on previous observations that sEH inhibition attenuates
cisplatin-induced nephrotoxicity by modulating nuclear factor-kB
signaling, we hypothesized that this strategy would also at-
tenuate cisplatin-induced renal apoptosis. Inhibition of sEH with
AR9273 [1-adamantan-1-yl-3-(1-methylsulfonyl-piperidin-4-yl-
urea)] reduced cisplatin-induced apoptosis through mechanisms
involving mitochondrial apoptotic pathways and by reducing re-
active oxygen species. Renal mitochondrial Bax induction following
cisplatin treatment was significantly decreased by treatment
of mice with AR9273 and these antiapoptotic effects involved
p38 mitogen-activated protein kinase signaling. Similar mech-
anisms contributed to reduced apoptosis in Ephx22/2 mice
treated with cisplatin. Moreover, in pig kidney proximal tubule
cells, cisplatin-induced mitochondrial trafficking of Bax and
cytochrome c, caspase-3 activation, and oxidative stress are
significantly attenuated in the presence of epoxyeicosatrienoic
acids (EETs). Collectively, these in vivo and in vitro studies
demonstrate a role for EETs in limiting cisplatin-induced
renal apoptosis. Inhibition of sEH represents a novel thera-
peutic strategy for protection against cisplatin-induced renal
damage.
Introduction
Cisplatin is a widely used chemotherapeutic for the treat-
ment of solid tumors. A dose-limiting toxicity associated with
cisplatin treatment is acute kidney injury (Pabla and Dong,
2008). Cisplatin treatment can lead to tubular cell injury and
death, resulting in the loss of renal function. Extensive stud-
ies have shown both inflammatory and apoptotic mechanisms
for cisplatin-induced acute kidney injury (Ramesh and Reeves,
2002; Zhang et al., 2007; Pabla and Dong, 2008, 2012;
Pabla et al., 2009). Numerous renoprotective strategies have
been proposed that target key signaling pathways involved in
cisplatin-induced necrosis and apoptosis, including tumor
necrosis factor-a (TNF-a), caspases, and mitogen-activated
protein kinases (MAPKs) (Pabla and Dong, 2008). A novel
renoprotective strategy recently proposed by our laboratory is
modulation of cytochrome P450 (P450) renal eicosanoid degra-
dation by soluble epoxide hydrolase (sEH) (Liu et al., 2012).
Epoxyeicosatrienoic acids (EETs) are products of CYP2C-
and CYP2J-mediated metabolism of arachidonic acid (Kroetz
and Zeldin, 2002; Spector et al., 2004;Wang et al., 2010). EETs
are further metabolized by sEH to dihydroxyeicosatrienoic
acids (DHETs). The EET eicosanoids are associated with a di-
verse set of biologic functions, including anti-inflammatory
and vasodilatory effects (Yang et al., 2007; Marino, 2009;Wang
et al., 2010). Modulation of EET levels by inhibition of sEH
has been proposed as a novel therapeutic approach for the
treatment of hypertension, renal disease, inflammation, pain,
and atherosclerosis (Wang et al., 2010). In a mouse model of
cisplatin-induced nephrotoxicity, genetic or pharmacological
inhibition of sEH markedly increased plasma epoxylipid
levels while attenuating renal damage and inflammation in
a nuclear factor (NF)-kB–dependent manner (Liu et al., 2012).
The ability of EETs to block apoptosis in cell culture (Jiang
et al., 2005; Yang et al., 2007; Dhanasekaran et al., 2008;
This work was supported by the University of California [Discovery Grant
Bio06-1-576]; the National Institutes of Health National Institute of Diabetes
and Digestive and Kidney Diseases [Grant R01-DK084147]; and in part by
Arête Therapeutics.
dx.doi.org/10.1124/mol.113.088302.
s This article has supplemental material available at molpharm.
aspetjournals.org.
ABBREVIATIONS: AC-DEVD-CHO, N-acetyl-L-a-aspartyl-L-a-glutamyl-N-(2-carbonyl-1-formylethyl)-L-valinamide; AR9273, 1-adamantan-1-yl-3-
(1-methylsulfonyl-piperidin-4-yl-urea); DAPI, 49,6-diamidino-2-phenylindole; DCF, 29,79-dichlorodihydroxyfluorescein; DCFH-DA, 29,79-dichlorodihy-
drofluorescin diacetate; EET, epoxyeicosatrienoic acid; EpETE, epoxyeicosatetraenoic acid; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
LLC-PK1, pig kidney proximal tubule cells; MAPK, mitogen-activated protein kinase; MS-PPOH, N-(methylsulfonyl)-2-(2-propynyloxy)-
benzenehexanamide; P450, cytochrome P450; PBS, phosphate-buffered saline; ROS, reactive oxygen species; SB203580, 4-(49-fluorophenyl)-2-(49-
methylsulfinylphenyl)-5-(49-pyridyl)-imidazole; sEH, soluble epoxide hydrolase; SOD, superoxide dismutase; TNF-a, tumor necrosis factor-a; TNFR,
tumor necrosis factor-a receptor.
925
http://molpharm.aspetjournals.org/content/suppl/2013/10/03/mol.113.088302.DC1
Supplemental material to this article can be found at: 
 at A
SPET Journals on July 12, 2019
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
Bodiga et al., 2009; Chen et al., 2009, 2011; Ma et al., 2010,
2012; Batchu et al., 2011; Liu et al., 2011; Zhao et al., 2012)
suggests that the renoprotective properties of sEH inhibition
might also be related to their effects on cisplatin-induced ap-
optosis. The antiapoptotic effects of EETs have been linked
to phosphoinositide 3-kinase/protein kinase B and MAPK
signaling pathways (Yang et al., 2007; Dhanasekaran et al.,
2008; Chen et al., 2009, 2011; Batchu et al., 2011; Liu et al.,
2011; Zhao et al., 2012). TNF-a signaling through both tumor
necrosis factor-a receptor (TNFR)1 and TNFR2 (Ramesh and
Reeves, 2003; Tsuruya et al., 2003) and the production of
reactive oxygen species (ROS) (Yao et al., 2007; El-Beshbishy
et al., 2011) are implicated in the apoptotic effects of cis-
platin. Cisplatin also induces apoptosis through the intrinsic
or mitochondrial pathway, resulting in Bax accumulation in
mitochondria, cytochrome c release, and caspase activation
(Huang et al., 2001; Lee et al., 2001; Park et al., 2002). In our
recent study, inhibition of sEH resulted in increases in
epoxylipid levels and concomitant decreases in cisplatin-
induced apoptosis (Liu et al., 2012). The mechanism for this
antiapoptotic effect of sEH inhibition is the focus of this study.
Materials and Methods
Reagents. Cisplatin, DAPI (49,6-diamidino-2-phenylindole), Mi-
tochondrial Isolation Kit, and Caspase-3 Activity Assay Kit were
purchased from Sigma-Aldrich (St. Louis, MO). The sEH chemical
inhibitor AR9273 [1-adamantan-1-yl-3-(1-methylsulfonyl-piperidin-4-
yl-urea)] was synthesized and kindly provided by Arête Therapeutics
(Hayward, CA). MS-PPOH [N-(methylsulfonyl)-2-(2-propynyloxy)-
benzenehexanamide] was purchased from Cayman Chemical (Ann
Arbor, MI). The ApoAlet Caspase Profiling Plate was purchased from
Clontech Laboratories, Inc. (Fitchburg, WI) and the Caspase-9 Activ-
ity Assay Kit was from Chemicon International, Inc. (Temecula, CA).
Primary antibodies against phosphorylated- or total-p38 MAPK,
precaspase-9, cleaved caspase-3, and cytochrome c were purchased
from Cell Signaling Technology (Danvers, MA). Innocyte Flow
Cytometric Cytochrome c Release Kit and Anti-Bax were products of
EMDMillipore (Temecula, CA), and the activated caspase-3 antibody
and superoxide dismutase (SOD) Activity Assay kit were from Abcam
(Cambridge, MA). OxiSelect Intracellular and In Vitro ROS assay kits
were purchased from Cell Biolabs, Inc. (San Diego, CA). GAPDH
(glyceraldehyde-3-phosphate dehydrogenase), goat anti-rabbit Alexa
Fluor 594 antibody, and goat anti-mouse or goat anti-rabbit Alexa
Fluor 488 antibody were from Life Technologies (Grand Island, NY).
Infrared IRDye-labeled secondary antibodies for Western blot were
from Li-Cor, Inc. (Lincoln, NE). PARIS reagents were purchased from
Ambion (Austin, TX). BCA Assay Kit was purchased from Pierce
(Rockford, IL).
Animal Experiments. C57BL/6 mice were purchased from
Charles River Laboratories (Wilmington, MA). In all studies, 8- to
10-week-old male mice weighing 20–25 g were used. Animal experi-
ments were conducted with adherence to the NIH Guide for the Care
and Use of Laboratory Animals and were approved by the Animal
Care andUseCommittee of theUniversity of California, San Francisco.
Cisplatin and AR9273 were freshly prepared in sterile saline or 1%
carboxymethylcellulose/0.1% Tween 80, respectively. C57BL/6 mice
were given 100 mg/kg AR9273 or vehicle daily by oral gavage starting
one day prior to cisplatin treatment and continuing for 5 days. A single
dose of 20 mg/kg cisplatin or an identical volume of sterile saline was
administered to mice by intraperitoneal injection. Mice were sacrificed
24, 48, or 72 hours postcisplatin treatment (30 minutes following the
last dose ofAR9273) and thekidneyswere flash frozenand storedat280°C
until analyzed.
Fig. 1. sEH inhibition attenuates cisplatin-induced p38 MAPK signaling
in vivo. Paraffin-embedded kidneys (3 mm) were immunostained with an
antibody against phospho-p38 MAPK (bright green) and the nuclei were
labeled with DAPI (blue). Cytosolic phosphorylated-p38 MAPK (green) is
noted with arrows and nuclear localization of phosphorylated-p38 MAPK
(turquoise) is marked with arrowheads. (A and B) Kidneys from saline-
and AR9273 (100 mg/kg daily by oral gavage)-treated mice collected at
72 hours and stained with antiphospho-p38 MAPK. (C) Kidney from a
cisplatin-treated (single 20 mg/kg dose) mouse collected at 72 hours and
stained with rabbit serum. (D–F) Cisplatin-treated mice (G–I) and cis-
platin plus AR9273–treated mice at 24 (D and G), 48 (E and H) and 72
hours (F and I), respectively. The bar indicates 50 mm. In J, renal lysates
prepared from kidneys harvested 72 hours after cisplatin treatment were
subjected to SDS-PAGE followed by immunoblotting for phosphorylated-
p38MAPK (p-p38; upper) or total-p38MAPK (t-p38; lower). Phosphorylated-
p38 MAPK was quantified using laser densitometry and is expressed
relative to total-p38 MAPK levels (K). The values shown are the mean 6
S.D. for three samples per group and are representative of five inde-
pendent measurements. Significant differences are indicated: ***P ,
0.001 cisplatin compared with saline control; †††P , 0.001 cisplatin
compared with cisplatin plus AR9273.
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Immunohistochemistry. Paraffin-embedded kidneys were sec-
tioned at 3 mm. Paraffin was removed with two washes with 100%
xylene for 3 minutes, followed by 1:1 xylene/ethanol for 3 minutes,
100% ethanol for 3 minutes, 95% ethanol for 3 minutes, 70% ethanol
for 3 minutes, 50% ethanol for 3 minutes and a final wash with tap
water. Kidney sections were stainedwithH&Eusing standardmethods.
The renal injury was scored by counting the number of apoptotic
tubules in the cortex and outer stripe of the outer medulla in 20 high-
power fields at 400 magnification. The analysis was performed by
a board-certified pathologist without knowledge of the experimental
groups. Immunohistochemistry was performed by incubating kidney
sections overnight at 4°C with antibodies against phosphorylated-p38
MAPK or the active form of caspase-3. A species-appropriate serum
was used as the staining control on 72-hour cisplatin-treated mice.
After three washes with phosphate-buffered saline (PBS), the slides
were incubated with a fluorescently conjugated secondary antibody
for 1 hour at room temperature or for overnight at 4°C, protected from
light. After three washes with PBS, images were captured using a
Retiga CCD-cooled camera and associated QCapture Pro software
(Qimaging, Surrey, BC, Canada).
Cell Culture and Immunocytochemistry. Pig kidney proximal
tubule (LLC-PK1) cells were purchased from American Type Culture
Collection (Manassas, VA) and cultured in M199 medium supple-
mented with 10% fetal bovine serum and 1% penicillin-streptomycin.
In brief, LLC-PK1 cells were treated with or without 3 mM EETs in
the presence or absence of 10 mMSB203580 [4-(49-fluorophenyl)-2-(49-
methylsulfinylphenyl)-5-(49-pyridyl)-imidazole], 500 mM N-acetylcys-
teine, 10 mM AR9273, or 3 mM MS-PPOH for 1 hour prior to 50-mM–
cisplatin treatment. After 20 hours of cisplatin treatment, the cells
were washed with cold PBS and fixed with 4% paraformaldehyde for
20 minutes at room temperature. Cells were then washed three times
with PBS, and incubated with a primary antibody against cytochrome c,
phosphorylated- or total-p38MAPK, or the active form of Bax in a way
similar to that described above. LLC-PK1 cell fractions for cytochrome c
immunocytochemistrywere specifically isolated and fixedwith Innocyte
Flow Cytometric Cytochrome c Release Kit (EMD Millipore) reagents
according to the manufacturer’s instructions.
Preparation of Mitochondrial Fractions. Mitochondrial frac-
tions were isolated with a mitochondrial isolation kit (Sigma-Aldrich).
In brief, at the conclusion of each treatment, kidneys or cells were
washed with cold PBS and centrifuged at 600g for 5 minutes. Tissue
or cell pellets were incubated with Extraction Buffer A for 10 minutes
on ice, homogenized for 10–30 strokes and centrifuged at 600g for 10
minutes. Supernatants were removed and centrifuged at 11,000g for
10 minutes. The mitochondrial fractions were resuspended as
suggested by the manufacturer. All centrifugations were carried out
at 4°C.
Western Blot. Kidney tissues were lysed with Ambion PARIS
reagents. Protein concentrations were quantified using a BCA assay
(Pierce). Protein aliquots from each sample were separated by SDS-
PAGE and transferred to a nitrocellulose membrane. The membranes
were blocked with PBS-0.1% Tween 20 buffer containing 5% nonfat
dried milk for 1 hour at room temperature and then probed overnight
at 4°C with a primary antibody against phosphorylated- or total-p38
MAPK, GAPDH, precaspase-9, cleaved caspase-3, or Bax-NT. Mem-
branes were rinsed three times with PBS–0.1% Tween 20, followed by
incubation with a secondary antibody for 1 hour at room temperature
or for overnight at 4°C. Proteins were detected and expression levels
were analyzed with Li-Cor Odyssey Software.
Caspase-2, -3, -8, and -9 Activity Enzyme Immunoassay.
Lysates from renal tissue and LLC-PK1 cells were used to detect
caspase-3, (Sigma-Aldrich), caspase-9 (Chemicon), and caspases-8 and
-2 (Clontech) activities. The assays were performed exactly as de-
scribed by the manufacturers.
Superoxide Dismutase Activity Assay. Briefly, renal or cell
lysates were homogenized in ice-cold 0.1 M Tris-HCl containing 0.5%
Triton X-100, 5 mM b-mercaptoethanol, and 0.1 mg/ml phenylmethane-
sulfonyl fluoride and centrifuged at 14000g for 5 minutes at 4°C to
remove cell debris. The assay was performed exactly as described by
the manufacturer (Abcam, Cambridge, MA). After incubation at 37°C
for 20 minutes absorbance was measured at 450 nm using a micro-
plate reader.
Reactive Oxygen Species Quantification. Reactive oxygen
species were measured using a fluorescence-based assay according
to the manufacturer’s protocol. The cell-permeable fluorogenic probe
DCFH-DA (29,79-dichlorodihydrofluorescin diacetate) diffuses into cells
and is deacetylated by cellular esterases to the nonfluorescent 29,79-
dichlorodihydrofluorescin, which is rapidly oxidized to highly fluores-
cent DCF (29,79-dichlorodihydroxyfluorescein) by ROS. In the LLC-PK1
Fig. 2. sEH inhibition attenuates cisplatin-induced activation of caspase-
3 in vivo. Paraffin-embedded kidneys (3 mm) were immunostained for an
activated form of caspase-3 (bright red) and DAPI (blue). The arrows
indicate cleaved caspase-3 and the bar denotes 50 mm. Activated caspase-3
is absent in kidneys collected at 72 hours from saline (A) and AR9273 (B)
treated mice; C is kidney from mice treated for 72 hours with cisplatin
stained with rabbit serum. (D–F) Representative kidney sections from
cisplatin treated mice while G–I are representative kidney sections from
cisplatin plus AR9273–treated mice at 24 (D and G), 48 (E and H), and 72
hours (F and I), respectively. Caspase-3 activity was measured in renal
lysates in the absence and presence of a caspase-3 inhibitor (AC-DEVD-
CHO) using an enzyme immunoassay. Values shown in J are the mean
6 S.D. from three samples. Significant differences are indicated: ***P ,
0.001 cisplatin compared with saline control; †††P , 0.001 cisplatin
compared with cisplatin plus AR9273.
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studies, cell culture plates were precoated with a 1DCFH-DA/media
solution for 30–60 minutes, washed three times with Dulbecco’s
PBS and used as described above. ROS levels were determined using
DCF standards supplied by the manufacturer (Cell Biolab, San Diego,
CA).
Terminal Deoxynucleotidyl Transferase–MediatedDigoxigenin-
Deoxyuridine Nick-End Labeling Assay. A terminal deoxynu-
cleotidyl transferase–mediated digoxigenin-deoxyuridine nick-end
labeling assay was performed with an in situ cell-death detection
kit, TMR Red (Roche Diagnostics, Mannheim, Germany). Cells were
seeded in 8-well chambers and were treated with cisplatin (50 mM) in
the presence or absence of the P450 inhibitor MS-PPOH (3 mM) or
purified 11,12-EET (3 mM) for 20 hours. Cells were then washed with
cold PBS and stained following the manufacturer’s directions. DAPI
staining was used for identifying nuclei. Apoptotic cells were counted
in five random fields at 200 magnification in triplicate samples.
Statistics. Values are expressed as mean 6 S.D. as indicated in
the figure legends. Differences between treatments were analyzed by
analysis of variance followed by Bonferroni post-hoc multiple com-
parison testing using GraphPad Prism 5. A P , 0.05 was considered
significant. All experiments were repeated two or three times and
representative results are shown.
Results
sEH Inhibition Attenuates Cisplatin-Induced Apoptotic
Signaling through p38 MAPK Activation In Vivo. We
have previously reported that pharmacological or genetic
inhibition of sEH attenuates cisplatin-induced apoptosis in
the kidney (Liu et al., 2012), although themechanism for this
antiapoptotic effect was not determined. Here, we investi-
gated the effect of pharmacological inhibition of sEH on p38
MAPK signaling. Cisplatin treatment caused tubular dam-
age and apoptosis in the cortex and outer stripe of the
medulla that was significantly attenuated by treatment with
the sEH inhibitor AR9273 (Supplemental Fig. 1). Apoptotic
tubules were visible by 48 hours after cisplatin treatment and
increased further by 72 hours (Supplemental Fig. 1, A–I).
Quantification of EETs and epoxyocatadecenoic acids and
their corresponding diols in plasma confirmed the inhibition
of sEH in vivo by AR9273 treatment (Supplemental Fig. 2).
Saline- or AR9273-treated mice had no detectable phosphorylated-
p38 MAPK in the kidney (Fig. 1, A and B). In contrast,
cisplatin treatment was associated with induction of p38
MAPK phosphorylation within 24 hours of administration
and phosphorylation of p38 MAPK increased dramatically
over the 72-hour period following cisplatin treatment (Fig. 1,
D–F). Inhibition of sEHwith AR9273 significantly attenuated
p38 MAPK phosphorylation induced by cisplatin (Fig. 1, G–I).
Western blots of renal tissue collected 72 hours after cisplatin
treatment confirmed the attenuation of cisplatin-induced p38
MAPK phosphorylation by AR9273 treatment (Fig. 1, J and
K). Similar results were observed in mice with a genetic
deletion of Ephx2. Cisplatin significantly induced the phos-
phorylation of p38 MAPK in Ephx21/1 mice (Supplemental
Fig. 3, B, D, F, and G) but not inEphx22/2mice (Supplemental
Fig. 3, A, C, F, and G).
sEH Inhibition Prevents Cisplatin-Induced Activa-
tion of Caspase-3 In Vivo. In apoptotic cells, caspase-3 has
been detected in the cytosol (Samali et al., 1999). In the
kidneys of cisplatin-treated mice, activated caspase-3 is
detected in the cytosol within 24 hours of treatment and
increases dramatically over the 72-hour period following
cisplatin treatment (Fig. 2, A–F). Inhibition of sEH with
AR9273 results in significant attenuation of the activated
caspase-3 levels that is most evident at 72 hours following
cisplatin administration (Fig. 2, G–I). Consistent with the im-
munohistochemistry results, cisplatin treatment resulted in
activation of caspase-3 that was attenuated by AR9273 treat-
ment (Fig. 2J). Activation of caspase-3 in renal lysates from
cisplatin-treated mice was prevented by the caspase-3 in-
hibitor AC-DEVD-CHO (N-acetyl-L-a-aspartyl-L-a-glutamyl-
N-(2-carbonyl-1-formylethyl)-L-valinamide).
sEH Inhibition Attenuates the Intrinsic Mitochon-
drial Apoptotic Pathway In Vivo. Cisplatin-induced apo-
ptosis has been previously associated with both an intrinsic
mitochondrial and an extrinsic death–receptor pathway
(Pabla and Dong, 2008). Cisplatin treatment of C57BL/6 mice
caused a decrease in renal cytosolic Bax levels (Fig. 3A) and
a corresponding increase in mitochondrial Bax levels (Fig.
3B). Cytosolic Bax levels decreased about 76% (Fig. 3C) while
mitochondrial levels increased almost 4-fold (Fig. 3D). This
translocation of Bax from the cytosol into the mitochondrial
membrane was attenuated by treatment with the sEH in-
hibitor AR9273. Consistent with the Bax trafficking data,
AR9273 treatment attenuated the activation of caspase-9 and
-8 (Fig. 4, A and B); this effect was most evident 72 hours
following cisplatin treatment. In contrast, caspase-2 was not
activated following cisplatin treatment (Fig. 4C). These data
support a major role for EETs in preventing cisplatin-induced
intrinsic apoptotic pathway activation in vivo.
sEH Inhibition Does Not Regulate Superoxide Dis-
mutase Activity but Attenuates the Increase in ROS In
Vivo. Cisplatin is associated with reduced SOD activity and
corresponding increases in reactive oxygen species (Yao et al.,
2007). Measurement of SOD activity in renal lysates from
cisplatin-treated mice showed a significant decrease in ac-
tivity 48 and 72 hours following treatment and this activity
was not restored in the cisplatin-treated mice by chemical
inhibition of sEH (Fig. 5A). Consistent with the reduction in
SOD activity, cisplatin treatment resulted in a significant
Fig. 3. sEH inhibition attenuates cisplatin-induced Bax translocation
into the mitochondria in vivo. Cytosolic (A) andmitochondrial (B) fractions
from kidneys harvested 72 hours following cisplatin treatment were sub-
jected to SDS-PAGE and immunoblotting with antibodies against activ-
ated Bax (upper) and GAPDH (lower). Bax expression (C and D) was
quantified using laser densitometry and expressed relative to GAPDH.
Values shown are the mean 6 S.D. from three samples. Significant dif-
ferences are indicated: *P , 0.01; ***P , 0.001, cisplatin compared with
saline control; ††P , 0.01 cisplatin compared with cisplatin plus AR9273.
NSB, nonspecific binding.
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increase in renal ROS levels that was attenuated by AR9273
treatment (Fig. 5B). Similar results were found in Ephx22/2
mice. The decrease in SOD activity induced by cisplatin treat-
ment was less in Ephx22/2mice compared with the Ephx21/1
mice (Supplemental Fig. 4A). Attenuation of the cisplatin-
induced increase in ROS levels in Ephx22/2 mice compared
with Ephx21/1 mice was consistent with the effect of sEH
inhibitor treatment (Supplemental Fig. 4B).
EETs Protect LLC-PK1 Cells from Cisplatin-Induced
Apoptosis. LLC-PK1 cells were used to further explore the
renoprotective properties of EETs. A range of EET concen-
trations was evaluated and 3 mMwas chosen for further study
since it gave a maximal effect. Cytochrome c release from
mitochondria is recognized as an early marker of apopto-
sis. Compared with LLC-PK1 cells treated with vehicle or
11,12-EET (Fig. 6, A and B), cisplatin treatment causes
Fig. 4. sEH inhibition attenuates cisplatin-induced caspase activation in
vivo. Caspase-9 (A), -8 (B), and -2 (C) activities were measured in renal
lysates using enzyme immunoassays. Values shown are the mean 6 S.D.
from three samples. Significant differences are indicated: **P , 0.01;
***P , 0.001, cisplatin compared with saline control; †P , 0.05; †††P ,
0.001, cisplatin compared with cisplatin plus AR9273.
Fig. 5. sEH inhibition does not prevent cisplatin-induced decreases in
renal SOD activity but attenuates increases in ROS in vivo. Renal lysates
harvested at 48 or 72 hours following cisplatin treatment were analyzed
for SOD activity (A) and ROS levels (B). Controls were renal lysates col-
lected at 72 hours from saline- or AR9273-treated mice. Values shown are
the mean 6 S.D. from three to five samples for each treatment group.
Significant differences are indicated: *P , 0.05; ***P , 0.001, cisplatin
compared with saline control; †P, 0.05, cisplatin compared with cisplatin
plus AR9273.
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release of cytochrome c from the mitochondria (Fig. 6C) and
this is prevented by treatment with 11,12-EET (Fig. 6D).
Similarly, cisplatin-induced activation of caspase-3 in LLC-
PK1 cells is attenuated by 11,12-EET treatment (Fig. 6, E–G).
Consistent with an increased caspase-3 activity, there was a
trend for a decreased level of precaspase-9 following treat-
ment of LLC-PK1 cells with cisplatin and partial attenuation
by 11,12-EET treatment. (Fig. 6, F and H).
The in vivo studies suggest that p38 MAPK signaling is
involved in the antiapoptotic effects of sEH inhibition. Treat-
ment of LLC-PK1 cells with cisplatin is associated with phos-
phorylation of p38 MAPK, and translocation of Bax into the
mitochondrial membrane (Fig. 7, A and B). The addition of
11,12- and 14,15-EETs (Fig. 7, E and G), but not 8,9-EET (Fig.
7C), attenuates cisplatin-induced p38 MAPK phosphorylation
and Bax translocation. Addition of the p38 MAPK inhibitor
SB203580 to EETs resulted in almost complete protection
from cisplatin-induced p38 MAPK phosphorylation and Bax
translocation (Fig. 7, D, F, and H). Similar results were found
if p38 MAPK phosphorylation and Bax were detected by
Western blotting (Supplemental Figs. 5 and 6) and the mag-
nitude of the EET effect was similar to that of a potent p38
MAPK inhibitor (Fig. 7, I–K; Supplemental Figs. 5 and 6).
Inhibition of endogenous epoxylipids with AR9273 had a
similar effect on p38 MAPK phosphorylation and Bax trans-
location as EET treatment (Supplemental Figs. 5 and 6).
Studies were also carried out using an inhibitor of P450
epoxygenases (MS-PPOH) to lower endogenous EET levels.
MS-PPOH itself had no apoptotic effects (Fig. 8, B and H) but
showed a trend toward increasing cisplatin-induced apoptosis
(Fig. 8, D, E, and H). The ability of P450 epoxygenase inhib-
ition to enhance apoptosis can be suppressed by supplemen-
tation with exogenous EETs (Fig. 8, F, G, and H).
Treatment of LLC-PK1 cells with regioisomeric EETs
reversed the modest cisplatin-induced decrease in SOD activ-
ity (Fig. 9A) and attenuated the increase in cisplatin-induced
ROS levels (Fig. 9B). The effect of EETs was similar to treat-
ment with the sEH inhibitor AR9273 or with the ROS scav-
enger N-acetylcysteine (Fig. 9, A and B).
Discussion
Apoptosis or programmed cell death plays an important role
in regulating mammalian physiology (Reed, 2002; Hanigan
and Devarajan, 2003; Reed et al., 2003). In animal models of
cisplatin-induced acute kidney injury, apoptosis is a prom-
inent feature (Ramesh and Reeves, 2002; Zhang et al., 2007;
Pabla and Dong, 2008, 2012; Pabla et al., 2009). Treatment
with p38 MAPK inhibitors prior to cisplatin significantly
decreases apoptosis in vivo and in vitro (Ramesh and Reeves,
2002, 2003, 2005), indicating that p38 MAPK signaling is
involved in cisplatin-induced renal injury (Ramesh and
Reeves, 2005). Overexpression of P450s significantly protects
Fig. 6. EETs protect LLC-PK1 cells from
cisplatin-induced cytochrome c release
and caspase-3 activation. LLC-PK1 cells
were treated with cisplatin in the absence
or presence of 11,12-EET (3 mM). Locali-
zation of cytochrome c (bright green) was
detected by immunocytochemistry (A–D).
DAPI staining is blue.Representative images
are shown for cells treated with vehicle
(A), 11,12-EET (B), cisplatin (C), or cis-
platin plus 11,12-EET (D). Mitochondrial
cytochrome c is labeled with arrows. The
bar indicates 10 mm. Caspase-3 activity
was measured in cell lysates in the ab-
sence and presence of the caspase-3 in-
hibitor AC-DEVD-CHO with an enzyme
immunoassay (E). These results are rep-
resentative of three independent experi-
ments. Values shown are the mean6 S.D.
from three samples. There was no effect of
ethanol on caspase activity in the absence
or presence of cisplatin (data not shown).
Significant differences are indicated: ***P,
0.001, cisplatin compared with control;
††P , 0.01, cisplatin compared with cis-
platin plus 11,12-EET. Caspase expression
(F) was detected by SDS-PAGE followed by
immunoblotting against cleaved caspase-3
(top), precaspase-9 (middle), or GAPDH (bot-
tom). The expression of cleaved caspase-3
(G) and precaspase-9 (H) was quantified
by laser densitometry and expressed re-
lative to GAPDH levels. Values shown are
the mean 6 S.D. from three samples. Sig-
nificant differences are indicated: ***P ,
0.001 cisplatin compared with vehicle
control.
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endothelial cells fromTNF-a–induced apoptosis, in part through
inhibition of extracellular signal-related kinase dephosphor-
ylation and activation of phosphoinositide 3-kinase/protein
kinase B signaling (Yang et al., 2007). Pretreatment with the
eicosanoids 17,18-EpETE (17,18-epoxyeicosatetraenoic acid),
14,15-EET and 11,12-EET prevents the phosphorylation of
p38MAPK induced by TNF-a in human bronchi (Morin, 2010)
and by As2O3 in Tca-8113 cells (Liu et al., 2011). Previous
studies have also shown that TNFR1/2–deficient mice are
resistant to cisplatin nephrotoxicity and that TNFR2 has
a key role in cisplatin-induced apoptosis (Ramesh and Reeves,
2003; Tsuruya et al., 2003). Considering these earlier studies
implicating EETs in antiapoptotic effects and our recent
finding that inhibition of sEH attenuates cisplatin-induced
TNF-a and TNFR1/2 induction (Liu et al., 2012), we hypoth-
esized that increased EET levels resulting from sEH inhib-
ition would protect against cisplatin-induced apoptosis by
interfering with p38 MAPK signaling.
Cytosolic p38 MAPK, and to a lesser extent nuclear p38
MAPK, are phosphorylated under apoptotic conditions (Kyriakis
and Avruch, 2001; Wood et al., 2009). In the current study, the
majority of phosphorylated-p38 MAPK was cytosolic, consis-
tent with previous studies (Raingeaud et al., 1995; Burger
et al., 1997; Kyriakis and Avruch, 2001; Wood et al., 2009).
Nuclear localization of phosphorylated-p38 MAPK is only
found at 72 hours following cisplatin treatment and may in-
dicate more severe apoptosis at this time.
Phosphorylation of p38 MAPK has been coupled to acti-
vated caspase-3 (Segreto et al., 2011). Caspases are synthe-
sized as inactive proenzymes and activated by cleavage at
specific Asp residues. Caspase-3, -8, and -9 have been detected
in the cytosol of apoptotic cells (Zhivotovsky et al., 1999). Our
results suggest that sEH inhibition attenuates cisplatin-
induced apoptosis largely by modulating caspase-3 activity,
although caspase-8 and -9 activities are also affected. The
involvement of caspase-3 is consistent with previous reports
of cisplatin-induced apoptosis (Zhan et al., 1999; Kaushal
et al., 2001) and EET analogs have recently been shown to at-
tenuate cisplatin-induced caspase-3 activity in Wistar-Kyoto
rats (Khan et al., 2013). The current studies do not rule out
a role for sEH inhibition in modulating caspase-independent
eventsmediating cisplatin-induced renal apoptosis (Cummings
and Schnellmann, 2002). sEH inhibition had no effect on
cisplatin-induced caspase-2 or -12 activity (data not shown),
suggesting that sEH inhibition has minimal effect on endo-
plasmic reticulum stress-signaling pathways that have been
previously associated with cisplatin nephrotoxicity (Pabla
and Dong, 2008). In contrast, recent studies in Wistar-Kyoto
rats showed a reduction in caspase-12 and other markers of
endoplasmic reticulum stress when rats were pretreated with
Fig. 7. EETs protect LLC-PK1 cells from cisplatin-induced p38 MAPK activation and Bax mitochondrial trafficking. LLC-PK1 cells were treated with
cisplatin in the absence and presence of regioisomeric EETs (3 mM) or the p38 MAPK inhibitor SB203580 (10 mM). Cells were stained with an antibody
against phosphorylated-p38 MAPK (green) or an active form of Bax (red). Nuclei were stained with DAPI (blue). Nuclear phosphorylated-p38 MAPK is
marked with an arrowhead (turquoise, merged images). Cell treatments were (A) vehicle control, (B) cisplatin, (C) cisplatin plus 8,9-, (E) 11,12-, or (G)
14,15-EET, (D) cisplatin plus 8,9-EET and SB203580, (F) 11,12-EET and SB203580, or (H) 14,15-EET and SB203580, (I) SB203580, (J) cisplatin, and (K)
cisplatin plus SB203580. The bar indicates 10 mm.
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EET analogs (Khan et al., 2013). Species differences or treat-
ment strategy might account for these differences in EET ef-
fects on the endoplasmic reticulum stress pathway.
Both an intrinsic mitochondrial and an extrinsic death–
receptor pathway have been associated with cisplatin-induced
renal apoptosis and acute kidney injury (Gordon and Gattone,
1986; Pabla and Dong, 2008). The proapoptotic protein Bax is
found in the cytosol of healthy cells and moves to the mito-
chondria upon initiation of apoptosis (Hsu et al., 1997; Wolter
et al., 1997). Bax2/2 mice were resistant to cisplatin-induced
apoptosis (Wei et al., 2007), suggesting that this is a key event
in cisplatin nephrotoxicity. In the current in vivo study, treat-
ment with AR9273 significantly attenuated the movement of
Bax into themitochondrial membrane following cisplatin treat-
ment, suggesting that elevated renal EET levels can interfere
with Bax trafficking in response to apoptotic signals. Cisplatin
has been previously found to induce apoptosis in LLC-PK1 cells
(Park et al., 2002; Seth et al., 2005) and these cells were used
to confirm a direct effect of EETs on Bax trafficking and p38
MAPK signaling. It has been shown that death signals induce
cytochrome c release from themitochondria upstreamof caspase-3
(Liu et al., 1996) and caspase-9 (Li et al., 1997) activation.
Cisplatin has also been shown to downregulate Bcl2 and
induce Bax mRNA in gastric adenocarcinoma cells (Korbakis
and Scorilas, 2012). Consistent with the current findings,
EET analogs increase the ratio of antiapoptotic to proapop-
totic signals in cisplatin-treated rats (Khan et al., 2013).
Among the EET regioisomers, 11,12- and 14,15-EET, but not
8,9- EET, have antiapoptotic properties in cisplatin-treated
LLC-PK1 cells, an effect that was similar to inhibition of p38
MAPK. Together, these results suggest that EETs attenuate
cisplatin-induced renal apoptosis at least in part by inhibiting
p38 MAPK phosphorylation upstream of the intrinsic mito-
chondrial apoptosis pathway.
Cisplatin treatment is associated with a decrease in cellular
SOD activity and corresponding increases in levels of reactive
oxygen species (Yao et al., 2007; El-Beshbishy et al., 2011). In
cells, EETs can upregulate SOD and reduce apoptosis and
Fig. 8. Inhibition of P450 epoxygenase activity enhances cisplatin-
induced apoptosis in LLC-PK1 cells. LLC-PK1 cells were treated with
cisplatin in the absence or presence of the P450 epoxygenase inhibitor
MS-PPOH (3 mM) or EETs (3 mM). Apoptotic cells were detected by
a terminal deoxynucleotidyl transferase–mediated digoxigenin-deoxyuri-
dine nick-end labeling assay and are stained red. Nuclei are indicated by
DAPI staining (blue). The bar indicates 25 mm. Representative images are
shown for cells treated with (A) vehicle, (B) MS-PPOH, (C) EETs, (D)
cisplatin, (E) cisplatin plus MS-PPOH, (F) cisplatin plus EETs, and (G)
cisplatin plus MS-PPOH and EETs. The number of apoptotic cells was
counted in five random fields at 200magnification and the values shown
are the mean 6 S.D. from three samples (H). Significant differences are
indicated: ***P , 0.001 compared with control; †P , 0.05, sample com-
pared with cisplatin alone.
Fig. 9. Treatment of LLC-PK1 cells with EETs or an sEH inhibitor at-
tenuates the effect of cisplatin on SOD activity and levels of ROS. LLC-PK1
cells were treated with cisplatin (50 mM) in the absence or presence of
regioisomeric EETs (3 mM), the ROS scavenger N-acetylcysteine (NAC;
500 mM) or the sEH inhibitor AR9273 (10 mM). Hydrogen peroxide (H2O2;
10mM), a ROS inducer, was added to cells as a positive control. SODactivity
(A) andROS levels (B) weremeasured and values shown are themean6S.D.
from three to five independent samples from each treatment. Significant
differences are indicated: ***P , 0.001, cisplatin or H2O2 compared with
control; †P , 0.05; ††P , 0.01; †††P , 0.001, cisplatin compared with cis-
platin plus EETs, AR9273, or NAC alone or in combination.
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cellular toxicity associated with arsenic trioxide treatment
(Liu et al., 2011). In the current study, SOD activity did de-
crease in cisplatin-treated kidneys but sEH inhibition or
genetic deletion of Ephx2 had only a modest effect on this
activity. However, direct measurement of reactive oxygen
species during sEH inhibition or in Ephx22/2 mice is con-
sistent with a role for EETs and possibly other epoxylipids in
controlling cisplatin-induced oxidative stress, resulting in re-
duced apoptosis. Additional properties of EETs beyond the
minimal effects on SOD activity likely contribute to the robust
change in levels of reactive oxygen species. These findings are
consistent with the ability of EET analogs to attenuate signals
of oxidative stress in cisplatin-treated rats (Khan et al., 2013).
The current study demonstrates a role for EETs in pro-
tection against cisplatin-induced apoptosis through at least
two distinct mechanisms. First, sEH inhibition or genetic dis-
ruption of Ephx2 interferes with p38 MAPK signaling up-
stream of the intrinsic mitochondrial apoptotic pathway. In
addition, oxidative stress is reduced by pharmacologic or
genetic alteration of sEH activity. Whether EETs also modu-
late extrinsic signaling pathways implicated in cisplatin-
induced renal apoptosis (Pabla and Dong, 2008) will require
further study. It is of interest to determine whether sEH
inhibition can effectively protect against renal apoptosis in-
duced by other mechanisms, including physical obstruction
and ischemia-reperfusion. Inhibition of sEH activity may
provide a novel therapeutic strategy for the prevention and
treatment of acute kidney injury.
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